Does Ozempic actually raise suicide risk? Here's what the data says
Quick answer
The psychiatric safety of semaglutide remains under active regulatory review, with the FDA and EMA monitoring adverse event reports but neither agency having confirmed a causal link between GLP-1 receptor agonists and suicidal ideation as of 2024. Patients with pre-existing psychiatric conditions taking GLP-1 medications should be monitored by their prescribing clinician, but this applies to most medication classes and does not constitute evidence of unique or confirmed psychiatric harm from semaglutide specifically. No large randomized controlled trial to date, including the SELECT trial, has demonstrated a statistically significant increase in suicidal events attributable to semaglutide.
Our take · Written by FormBlends editorial team · Reviewed by FormBlends Medical Team· This is not a transcript. It is our independent review of the video above.
What did @drreza_t actually say?
The creator claims a new study found Ozempic "increased the risk of suicidal thoughts and behaviors by 45%" and that the risk jumps "over 400%" for people already on antidepressants. He concludes this means Ozempic isn't worth taking and suggests a personal trainer and nutritionist are better alternatives. He frames this as a well-controlled study that accounted for baseline depression linked to obesity.
To his credit, he does tell viewers to talk to a qualified health professional before making changes. But the headline numbers he leads with, and the certainty with which he delivers them, are doing a lot of heavy lifting here. The 45% and 400% figures need serious context before anyone should panic or stop a prescribed medication.
Does the science back this up?
Not cleanly. The study most likely being referenced is a 2023 pharmacovigilance analysis using the FDA Adverse Event Reporting System (FAERS), which flagged a disproportionate signal for suicidal ideation with semaglutide. But FAERS data is not designed to establish causation, and the signal has been contested.
The European Medicines Agency (EMA) reviewed GLP-1 receptor agonist safety data in 2023 and 2024 and concluded there was no confirmed causal link between semaglutide and suicidal ideation. Larger observational studies, including work by Gorfinkel et al. (2024, JAMA Internal Medicine), found no statistically significant increase in suicidal events among GLP-1 users compared to matched controls. The FDA added a warning to monitor for depression and suicidal ideation, but a warning is not a confirmed causal association. The creator presents a preliminary signal as settled science, and that's a meaningful distortion.
What did they get wrong (or right)?
The creator got a few things partially right. GLP-1 receptors are expressed in brain regions involved in mood regulation, so a biological mechanism isn't implausible. The FDA has flagged this for monitoring. And he's correct that controlling for baseline depression linked to obesity matters in these analyses.
But the 45% relative risk figure, presented without mentioning the absolute risk, the data source, or the study's limitations, is misleading. A 45% increase in a rare event can represent a very small absolute difference. The 400% figure for antidepressant users is the kind of subgroup statistic that requires extreme caution. Subgroup analyses in pharmacovigilance databases are prone to confounding. People on antidepressants already have elevated baseline psychiatric risk. The creator says the study "did a really good job" controlling for confounders, but it's not clear which study he's referencing, and no citation is provided. Presenting unverified relative risk numbers as a reason to avoid a medication that has demonstrated cardiovascular and metabolic benefits in large randomized trials is irresponsible framing.
What should you actually know?
The honest answer is that the psychiatric safety of GLP-1 receptor agonists is still being studied, and that uncertainty is real and worth taking seriously. What isn't warranted is treating a pharmacovigilance signal as a confirmed finding.
The SELECT trial (Lincoff et al., 2023, New England Journal of Medicine), a large randomized controlled trial of semaglutide in people with obesity and cardiovascular disease, did not show a significant increase in psychiatric adverse events. The FDA's 2024 review of GLP-1 safety data, specifically examining suicidality, did not find sufficient evidence to require a boxed warning. If you're on semaglutide and experiencing mood changes, that absolutely warrants a conversation with your prescriber. But stopping a prescribed medication because of a TikTok video citing an unspecified study is not the right move. The creator's broader point about lifestyle being important is fair. But framing GLP-1 medications as shortcuts versus the "natural" way is a false choice for many patients with obesity-related metabolic disease.
Video review standard
Clinical fact-check snapshot
FormBlends treats social health videos as a starting point, then checks the claim against medical context, source quality, safety limits, and whether licensed provider review belongs in the next step.
Evidence signal
Source-backed review
Regulatory reality
Compounded Semaglutide access requires the right clinical path
Safety screen
Viral claims can miss contraindications, dose escalation, medication interactions, and quality-control risks.
This page currently connects to 8 source-backed evidence items through visible references or structured citation data.
PubMed evidence trail
Research sources used to frame this page
For Does Ozempic actually raise suicide risk? Here's what the data says, FormBlends checks the page topic against primary trials, systematic reviews, guidelines, and current PubMed-indexed literature where available. These citations are context, not medical advice, proof of eligibility, or a claim that every study applies to every patient.
Once-Weekly Semaglutide in Adults with Overweight or Obesity
Primary STEP 1 trial source for semaglutide weight-management efficacy and adverse-event context.
PubMed
Effect of Continued Weekly Subcutaneous Semaglutide vs Placebo on Weight Loss Maintenance
Used for maintenance, discontinuation, and weight-regain discussions after semaglutide response.
PubMed
Efficacy of GLP-1 Receptor Agonists on Weight Loss, BMI, and Waist Circumference
A broad meta-analysis anchor for GLP-1 weight-loss effect and class-level comparisons.
PubMed
Discontinuing glucagon-like peptide-1 receptor agonists and body habitus
Used for pages discussing stopping therapy, weight regain, and long-term planning.
PubMed
Provider decision path
Use local research to choose a safer review path
Direct answer
Compounded Semaglutide is best used to compare access, oversight, pricing, pharmacy quality, and patient support before starting care.
Evidence check
Directory pages should connect local intent with provider standards, pharmacy transparency, and practical next steps.
Safety check
Provider quality, pharmacy source, prescribing model, and follow-up support can matter as much as the medication name.
Next step
Compare providers, services and access requirements in the directory before contacting a suitable care team.
Claim path
Keep researching this semaglutide video claims cluster
Best for searchers comparing social semaglutide claims with GLP-1 eligibility, outcomes, and safety context.
Claim verdict
The useful answer behind this video
Claim being checked
The psychiatric safety of semaglutide remains under active regulatory review, with the FDA and EMA monitoring adverse event reports but neither agency having confirmed a causal link between GLP-1 receptor agonists and suicidal ideation as of 2024.
FormBlends verdict
The psychiatric safety of semaglutide remains under active regulatory review, with the FDA and EMA monitoring adverse event reports but neither agency having confirmed a causal link between GLP-1 receptor agonists and suicidal ideation as of 2024. Patients with pre-existing psychiatric conditions taking GLP-1 medications should be monitored by their prescribing clinician, but this applies to most medication classes and does not constitute evidence of unique or confirmed psychiatric harm from semaglutide specifically. No large randomized controlled trial to date, including the SELECT trial, has demonstrated a statistically significant increase in suicidal events attributable to semaglutide.
Patient-safe next step
Compare the claim with the Compounded Semaglutide guide, safety notes, access rules, and a licensed-provider review.
What to do with this video
Use the clip as a claim to verify, not a treatment plan
What it helps with
- The psychiatric safety of semaglutide remains under active regulatory review, with the FDA and EMA monitoring adverse event reports but neither agency having confirmed a causal link between GLP-1 receptor agonists and suicidal ideation as of 2024. Patients with pre-existing psychiatric conditions taking GLP-1 medications should be monitored by their prescribing clinician, but this applies to most medication classes and does not constitute evidence of unique or confirmed psychiatric harm from semaglutide specifically. No large randomized controlled trial to date, including the SELECT trial, has demonstrated a statistically significant increase in suicidal events attributable to semaglutide.
- The FDA and EMA have both reviewed GLP-1 and suicidality data as of 2024 and neither agency confirmed a causal link or issued a boxed warning.
- The SELECT trial (Lincoff et al., 2023, NEJM) involving over 17,000 participants found no significant increase in psychiatric adverse events with semaglutide versus placebo.
What it may miss
- It may not cover eligibility, contraindications, medication interactions, lab history, or dose escalation.
- Compounded Semaglutide decisions still need source quality, legal access, and provider oversight checks.
- Social video captions rarely show the full evidence base behind a claim.
Best next step
Compare the claim against the Compounded Semaglutide guide, cost path, safety notes, and provider review before acting.
Review Compounded SemaglutideWhat You'll Learn
- The FDA and EMA have both reviewed GLP-1 and suicidality data as of 2024 and neither agency confirmed a causal link or issued a boxed warning.
- The SELECT trial (Lincoff et al., 2023, NEJM) involving over 17,000 participants found no significant increase in psychiatric adverse events with semaglutide versus placebo.
- Relative risk figures like 45% are meaningless without absolute risk data. A 45% increase in a very rare event may represent a negligible real-world difference.
- FAERS adverse event databases, the likely source of the figures cited, are hypothesis-generating tools, not causal evidence. They capture reports, not confirmed drug effects.
- Patients on antidepressants have elevated baseline rates of suicidal ideation independent of any medication, making subgroup comparisons in this population especially prone to confounding.
- If you are experiencing mood changes while on any GLP-1 medication, contact your prescriber. Do not stop a prescribed medication based on social media content without medical guidance.
- No large randomized controlled trial to date has demonstrated semaglutide causes suicidal ideation, though ongoing monitoring and further research are appropriate given biological plausibility.
Interested in GLP-1 or peptide therapy?
Get matched with licensed-provider review to help decide if it is right for you.
About the Creator
Dr. Reza T · TikTok creator
57.8K views on this video
Wow guys what do you think? Increased risk of suicidal thoughts due to taking ozempic. I dont think thats worth it at all.
Sources & references
Citations extracted from our medical team's review. Click any citation to search PubMed.
Read More on This Topic
Our written guides go deeper with dosing details, comparison tables, and medical-team reviewed protocols.
Not medical advice. This video was made by Dr. Reza T, not by FormBlends. Our write-up above is an editorial review, not a medical recommendation. Talk to your doctor before making any decisions about medications or treatments.